Vir Biotechnology, Inc. VIR
Set alert
At close · Oct 30
After hours · Oct 30, 6:53 PM ET
- YTD
- +87.40%
- 1 year
- +90.56%
- Open
- 11.63
- Prev close
- 11.75
- Mkt cap
- 1.91B
- Vol
- 1.27M
- Avg vol
- 1.92M
- EPS
- -1.76
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 11.18
- High
- 11.84
- Forward P/E
- -4.54
- Beta
- 1.59
- Short ratio
- 7.15
- Inst. own
- 84.42%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 10.90
- 200-d avg
- 9.50
- 1y target
- 21.00
5D chart
Signals (100)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 12:35 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:35 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:15 PM | 2 days ago |
| RSI: Oversold | Oct 30, 12:05 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 11:30 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:10 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:55 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 10:45 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:35 AM | 2 days ago |
| RSI: Oversold | Oct 30, 10:15 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 9:45 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:40 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:40 AM | 2 days ago |
| SMA: Bullish | Oct 29, 3:25 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:25 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:15 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:20 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:15 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:15 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:00 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:55 PM | 3 days ago |
| RSI: Oversold | Oct 29, 1:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 11:50 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 11:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:10 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:45 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:40 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:10 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:50 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:45 AM | 3 days ago |
| SMA: Bearish | Oct 29, 9:40 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:10 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:40 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:15 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:10 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 11:55 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:00 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 10:35 AM | 4 days ago |
| RSI: Overbought | Oct 28, 10:00 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 9:50 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 4 days ago |
| RSI: Overbought | Oct 28, 9:40 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 4 days ago |
| RSI: Overbought | Oct 27, 2:50 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:05 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:35 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:30 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 11:40 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:40 AM | 5 days ago |
| RSI: Overbought | Oct 27, 10:40 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:20 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:35 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:35 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 9:35 AM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:30 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:15 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:45 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:45 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:15 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:10 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 1:50 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 1:45 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 1:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:00 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:30 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 12:30 PM | 6 days ago |
| RSI: Overbought | Oct 26, 12:15 PM | 6 days ago |
| RSI: Overbought | Oct 26, 11:45 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:00 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:55 AM | 6 days ago |
| SMA: Bullish | Oct 26, 10:50 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:40 AM | 6 days ago |
| SMA: Bullish | Oct 26, 10:35 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 6 days ago |
News
4 days ago businesswire.com
Vir Biotechnology Announces Appointment of Suzanne Topalian to its Board of Directors
SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced the appointment of Suzanne Topalian, M.D., to its Board of Directors, effective October 27, 2026. Dr.…
5 days ago seekingalpha.com
Vir Biotechnology: A Big Pharma Collaboration And 2 Clinical Catalysts This Quarter
VIR's PRO-XTEN platform has attracted major pharma collaborations, validating its dual-masked T-cell engager technology for oncology and solid tumors. Near-term catalysts include ECLIPSE program…
1 week ago defenseworld.net
Critical Survey: REGENXBIO (NASDAQ:RGNX) versus Vir Biotechnology (NASDAQ:VIR)
REGENXBIO (NASDAQ: RGNX - Get Free Report) and Vir Biotechnology (NASDAQ: VIR - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two…
2 weeks ago zacks.com
Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth?
Gilead Sciences expands its oncology pipeline through a Vir Biotechnology deal worth up to $1.74 billion in additional milestones, targeting three novel cancer therapies.
2 weeks ago benzinga.com
Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments
Vir Biotechnology Inc. (NASDAQ:VIR) announced a major collaboration with Gilead Sciences Inc. (NASDAQ:GILD) to create three novel T-cell engagers (TCEs) aimed at treating solid tumors.
2 weeks ago benzinga.com
Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments
Vir Biotechnology and Gilead collaborate on novel T-cell engagers for solid tumors in a deal worth up to $1.87 billion, plus royalties.
-
2 weeks ago benzinga.com
Vir Biotechnology Signs Up To $1.875B Gilead Deal For 3 Cancer Drug Candidates; Gilead To Pay $65M Cash Upfront And Buy 1,765,486 Shares At $14.16 Each, For A Total Of $25M, Plus Up To $1.785B In Milestones And Royalties
Under the terms of the agreement, Vir Biotechnology will be responsible for discovery, design and optimization of three novel PRO-XTEN® dual-masked TCE development candidates targeting selected solid…
-
2 weeks ago benzinga.com
Vir Biotechnology Announces Collaboration, License Agreement With Gilead To Discover, Engineer Three PRO-XTEN Dual-Masked T-Cell Engager Development Candidates Targeting Selected Solid Tumor-Associated Antigens
- Collaboration combines Vir Biotechnology’s T-cell engager discovery, AI-enabled protein engineering and clinically-validated PRO-XTEN® masking technology with Gilead’s oncology development and…
2 weeks ago businesswire.com
Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced a collaboration and license agreement with Gilead to discover and engineer three novel PRO-XTEN® dual-masked…
-
3 weeks ago benzinga.com
Vir Biotechnology Receives FDA Fast Track Designation For VIR-5500 To Treat Metastatic Castration-Resistant Prostate Cancer
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to VIR-5500, a PSMA-targeted PRO-XTEN® dual-masked T-cell engager…
3 weeks ago businesswire.com
Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to VIR-5500, a PSMA-targeted…
3 weeks ago defenseworld.net
uniQure (NASDAQ:QURE) and Vir Biotechnology (NASDAQ:VIR) Critical Review
Vir Biotechnology (NASDAQ: VIR - Get Free Report) and uniQure (NASDAQ: QURE - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two…
-
3 weeks ago benzinga.com
HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $22
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Vir Biotechnology (NASDAQ:VIR) with a Buy and raises the price target from $20 to $22.
3 weeks ago gurufocus.com
Vir Biotechnology Appoints David Liu as Chief Medical Officer
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of David Liu, M.D., Ph.D., as Executive Vice President and Chief Medical Officer (CMO), ef
3 weeks ago businesswire.com
Vir Biotechnology Appoints David Liu as Chief Medical Officer
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of David Liu, M.D., Ph.D., as Executive Vice President and Chief Medical Officer (CMO), effective…
-
3 weeks ago benzinga.com
Vir Biotechnology To Reveal Expanded Phase 2 SOLSTICE Results for Elebsiran And Tobevibart In Hepatitis Delta at AASLD’s The Liver Meeting 2026
Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of elebsiran and tobevibart for chronic hepatitis delta…
3 weeks ago businesswire.com
Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD's The Liver Meeting® 2026
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of elebsiran and…
-
1 month ago benzinga.com
Vir Biotechnology Appoints Aziz Sawaf CFO, Effective Oct. 5
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Aziz Sawaf, MBEE, MBA, CFA, as Executive Vice President and Chief Financial Officer (CFO), effective October 5, 2026. Mr.…
1 month ago businesswire.com
Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer.
1 month ago seekingalpha.com
Vir Biotechnology: Astellas Deal Highlights The Platform's Value
Vir Biotechnology is now a two-engine company, with major pharma partnerships and a fully enrolled hepatitis delta phase 3 program. Gilead's bulevirtide launch is expanding hepatitis delta diagnosis,…
1 month ago defenseworld.net
Engineers Gate Manager LP Sells 121,964 Shares of Vir Biotechnology, Inc. $VIR
Engineers Gate Manager LP trimmed its stake in Vir Biotechnology, Inc. (NASDAQ: VIR) by 48.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange…
1 month ago defenseworld.net
Head-To-Head Comparison: Crescent Biopharma (NASDAQ:CBIO) vs. Vir Biotechnology (NASDAQ:VIR)
Vir Biotechnology (NASDAQ: VIR - Get Free Report) and Crescent Biopharma (NASDAQ: CBIO - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare…
1 month ago defenseworld.net
Bank of New York Mellon Corp Makes New $7.08 Million Investment in Vir Biotechnology, Inc. $VIR
Bank of New York Mellon Corp bought a new stake in Vir Biotechnology, Inc. (NASDAQ: VIR) during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities…
2 months ago businesswire.com
Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, President and Chief Executive Officer, will participate in a…
2 months ago defenseworld.net
Algert Global LLC Purchases 315,969 Shares of Vir Biotechnology, Inc. $VIR
Algert Global LLC grew its holdings in shares of Vir Biotechnology, Inc. (NASDAQ: VIR) by 64.6% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The firm owned…
2 months ago defenseworld.net
ADAR1 Capital Management LLC Acquires New Shares in Vir Biotechnology, Inc. $VIR
ADAR1 Capital Management LLC bought a new stake in Vir Biotechnology, Inc. (NASDAQ: VIR) during the second quarter, according to the company in its most recent filing with the Securities and Exchange…
2 months ago seekingalpha.com
Vir Biotechnology, Inc. (VIR) Q2 2026 Earnings Call Transcript
Vir Biotechnology, Inc. (VIR) Q2 2026 Earnings Call Transcript
-
2 months ago benzinga.com
Vir Biotechnology Q2 EPS $0.47 Beats $0.18 Estimate, Sales $238.946M Beat $216.456M Estimate
Vir Biotechnology (NASDAQ:VIR) reported quarterly earnings of $0.47 per share which beat the analyst consensus estimate of $0.18 by 161.11 percent. This is a 158.75 percent increase over losses of…
-
4 months ago benzinga.com
Morgan Stanley Maintains Overweight on Vir Biotechnology, Raises Price Target to $27
Morgan Stanley analyst Michelle Gilson maintains Vir Biotechnology (NASDAQ:VIR) with a Overweight and raises the price target from $23 to $27.
-
5 months ago benzinga.com
Leerink Partners Maintains Outperform on Vir Biotechnology, Raises Price Target to $21
Leerink Partners analyst Roanna Ruiz maintains Vir Biotechnology (NASDAQ:VIR) with a Outperform and raises the price target from $20 to $21.
-
5 months ago benzinga.com
Vir Biotechnology To Present Data From Its Phase 2 SOLSTICE Study Of Obevibart And Elebsiran Combination To Treat Chronic Hepatitis Delta
Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of tobevibart and elebsiran for chronic hepatitis delta…
-
5 months ago benzinga.com
Vir Biotechnology Q1 2026 GAAP EPS $(0.85) Up From $(0.88) YoY, Sales $(29.000K) Down From $3.032M YoY.
Vir Biotechnology (NASDAQ:VIR) reported quarterly losses of $(0.85) per share. This is a 3.41 percent increase over losses of $(0.88) per share from the same period last year. The company reported…
-
6 months ago benzinga.com
Vir Biotech Doses First Patient In Phase 1 Expansion Trial Of VIR-5500 For Metastatic Prostate Cancer
Phase 1 trial designed to assess the safety, pharmacokinetics and preliminary efficacy of VIR-5500 in both early and late-line metastatic castration-resistant prostate cancer (mCRPC) and metastatic…
8 months ago benzinga.com
Semtech To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Wednesday
Wall Street analysts changed outlook on top names. For full view of changes, including upgrades/downgrades, see analyst ratings page.
-
8 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $20
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Vir Biotechnology (NASDAQ:VIR) with a Buy and raises the price target from $15 to $20.
8 months ago benzinga.com
C3.ai Posts Downbeat Results, Joins Trade Desk, FTAI Aviation And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
C3.ai Posts Downbeat Results, Joins Trade Desk, FTAI Aviation And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
8 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
8 months ago benzinga.com
Why Marriott Vacations Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket
Why Marriott Vacations Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket
8 months ago benzinga.com
Nasdaq Gains Over 1%; Keurig Dr Pepper Earnings Top Views
Nasdaq Gains Over 1%; Keurig Dr Pepper Earnings Top Views
8 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
8 months ago benzinga.com
Henry Schein, Vir Biotechnology, Ultra Clean Holdings And Other Big Stocks Moving Higher On Tuesday
Henry Schein, Vir Biotechnology, Ultra Clean Holdings And Other Big Stocks Moving Higher On Tuesday
8 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
8 months ago benzinga.com
Why Keysight Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
Why Keysight Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
-
8 months ago benzinga.com
Earnings Scheduled For February 23, 2026
Earnings Scheduled For February 23, 2026
12 months ago benzinga.com
Earnings Scheduled For November 5, 2025
Earnings Scheduled For November 5, 2025
1 year ago benzinga.com
This Astera Labs Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday
This Astera Labs Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday
1 year ago benzinga.com
This Southwest Gas Analyst Turns Bullish; Here Are Top 2 Upgrades For Friday
This Southwest Gas Analyst Turns Bullish; Here Are Top 2 Upgrades For Friday
1 year ago benzinga.com
This Oddity Tech Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
This Oddity Tech Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session